ACE inhibitors and COVID-19: We don't know yet.
作者信息
Khashkhusha Taqua R, Chan Jeffrey Shi Kai, Harky Amer
机构信息
School of Medicine, University of Liverpool, Liverpool, United Kingdom.
Faculty of Medicine, The Chinese University of Hong Kong, Shatin, New Territories, Hong Kong.
出版信息
J Card Surg. 2020 Jun;35(6):1172-1173. doi: 10.1111/jocs.14582. Epub 2020 Apr 27.
Abstract
摘要
相似文献
1
ACE inhibitors and COVID-19: We don't know yet.血管紧张素转换酶抑制剂与2019冠状病毒病：我们尚不清楚。
J Card Surg. 2020 Jun;35(6):1172-1173. doi: 10.1111/jocs.14582. Epub 2020 Apr 27.
2
COVID-19 and cardiovascular disease: What we know, what we think we know, and what we need to know.2019冠状病毒病与心血管疾病：我们已知的、我们自认为已知的以及我们需要了解的情况。
J Mol Cell Cardiol. 2020 Jul;144:12-14. doi: 10.1016/j.yjmcc.2020.04.026. Epub 2020 Apr 24.
3
The role of ACEIs/ARBs in COVID-19: Friend or foe?血管紧张素转换酶抑制剂/血管紧张素Ⅱ受体阻滞剂在2019冠状病毒病中的作用：是友还是敌？
Med Hypotheses. 2020 Sep;142:109810. doi: 10.1016/j.mehy.2020.109810. Epub 2020 May 5.
4
Outcomes in Patients with COVID-19 Infection Taking ACEI/ARB.COVID-19 感染患者服用 ACEI/ARB 的结果。
Curr Cardiol Rep. 2020 Apr 14;22(5):31. doi: 10.1007/s11886-020-01291-4.
5
Would ACEIs/ARBs be beneficial for COVID-19 patients without hypertension?血管紧张素转换酶抑制剂/血管紧张素Ⅱ受体阻滞剂对无高血压的新冠患者有益吗？
Pharmacol Res. 2020 Sep;159:104959. doi: 10.1016/j.phrs.2020.104959. Epub 2020 Jun 4.
6
Drugs and the renin-angiotensin system in covid-19.新冠病毒肺炎中的药物与肾素-血管紧张素系统
BMJ. 2020 Apr 2;369:m1313. doi: 10.1136/bmj.m1313.
7
Sound Science before Quick Judgement Regarding RAS Blockade in COVID-19.在对COVID-19中的RAS阻断进行快速判断之前的可靠科学依据。
Clin J Am Soc Nephrol. 2020 May 7;15(5):714-716. doi: 10.2215/CJN.03530320. Epub 2020 Mar 27.
8
ACEI/ARB therapy in COVID-19: the double-edged sword of ACE2 and SARS-CoV-2 viral docking.COVID-19中的ACEI/ARB治疗：ACE2与SARS-CoV-2病毒对接的双刃剑
Crit Care. 2020 Jul 31;24(1):475. doi: 10.1186/s13054-020-03195-9.
9
[Hypertension and RAAS inhibition in times of COVID-19 - current recommendations of the European Society of Hypertension.].[2019冠状病毒病时期的高血压与肾素-血管紧张素-醛固酮系统抑制——欧洲高血压学会的当前建议。]
MMW Fortschr Med. 2020 May;162(9):67-69. doi: 10.1007/s15006-020-0483-y.
10
Coronavirus Disease 2019 (COVID-19) Infection and Renin Angiotensin System Blockers.2019冠状病毒病（COVID-19）感染与肾素-血管紧张素系统阻滞剂
JAMA Cardiol. 2020 Jul 1;5(7):745-747. doi: 10.1001/jamacardio.2020.1282.
引用本文的文献
1
Lisinopril increases lung ACE2 levels and SARS-CoV-2 viral load and decreases inflammation but not disease severity in experimental COVID-19.在实验性新冠肺炎中，赖诺普利可提高肺部血管紧张素转换酶2（ACE2）水平和严重急性呼吸综合征冠状病毒2（SARS-CoV-2）病毒载量，并减轻炎症，但不会降低疾病严重程度。
Front Pharmacol. 2024 Jul 12;15:1414406. doi: 10.3389/fphar.2024.1414406. eCollection 2024.
2
Stratification of hypertension and SARS-CoV-2 infection by quantitative NMR spectroscopy of human blood serum.通过人血清定量核磁共振波谱对高血压和SARS-CoV-2感染进行分层。
Commun Med (Lond). 2023 Oct 16;3(1):145. doi: 10.1038/s43856-023-00365-y.
3
Blood ACE2 Protein Level Correlates with COVID-19 Severity.血液 ACE2 蛋白水平与 COVID-19 严重程度相关。
Int J Mol Sci. 2023 Sep 11;24(18):13957. doi: 10.3390/ijms241813957.
4
Arterial Hypertension in Patients with COVID-19 - Neural Network Model.2019冠状病毒病患者的动脉高血压——神经网络模型
Acta Inform Med. 2022 Mar;30(1):25-28. doi: 10.5455/aim.2022.30.25-28.
5
The effect of various compounds on the COVID mechanisms, from chemical to molecular aspects.各种化合物对 COVID 机制的影响，从化学到分子方面。
Biophys Chem. 2022 Sep;288:106824. doi: 10.1016/j.bpc.2022.106824. Epub 2022 May 12.
6
Insight into prognostics, diagnostics, and management strategies for SARS CoV-2.对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）的预后、诊断和管理策略的洞察。
RSC Adv. 2022 Mar 11;12(13):8059-8094. doi: 10.1039/d1ra07988c. eCollection 2022 Mar 8.
7
Human placenta-derived amniotic epithelial cells as a new therapeutic hope for COVID-19-associated acute respiratory distress syndrome (ARDS) and systemic inflammation.人胎盘来源的羊膜上皮细胞作为治疗新型冠状病毒肺炎相关急性呼吸窘迫综合征（ARDS）和全身炎症的新希望。
Stem Cell Res Ther. 2022 Mar 25;13(1):126. doi: 10.1186/s13287-022-02794-3.
8
What we have learned from the COVID-19 pandemic: Time to think outside the box, maybe far outside.从 COVID-19 大流行中我们所学到的：是时候跳出固有思维了，也许要远远地跳出去。
Clin Dermatol. 2021 Jan-Feb;39(1):107-117. doi: 10.1016/j.clindermatol.2020.12.020. Epub 2020 Dec 16.
9
COVID-19 pandemic: the implications of the natural history, challenges of diagnosis and management for care in sub-Saharan Africa.新冠疫情：撒哈拉以南非洲地区自然史的影响、诊断挑战及护理管理
Beni Suef Univ J Basic Appl Sci. 2021;10(1):16. doi: 10.1186/s43088-021-00106-x. Epub 2021 Mar 17.
10
Interaction effects between angiotensin-converting enzyme inhibitors or angiotensin receptor blockers and steroid or antiviral therapies in COVID-19: A population-based study.血管紧张素转换酶抑制剂或血管紧张素受体阻滞剂与类固醇或抗病毒疗法在2019冠状病毒病中的相互作用：一项基于人群的研究。
J Med Virol. 2021 May;93(5):2635-2641. doi: 10.1002/jmv.26904. Epub 2021 Mar 9.
本文引用的文献
1
Renin-angiotensin system inhibitors improve the clinical outcomes of COVID-19 patients with hypertension.血管紧张素转化酶抑制剂改善合并高血压的 COVID-19 患者的临床结局。
Emerg Microbes Infect. 2020 Dec;9(1):757-760. doi: 10.1080/22221751.2020.1746200.
2
Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis.合并症的患病率及其对 SARS-CoV-2 感染患者的影响：系统评价和荟萃分析。
Int J Infect Dis. 2020 May;94:91-95. doi: 10.1016/j.ijid.2020.03.017. Epub 2020 Mar 12.
3
Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2.全长人血管紧张素转化酶 2 识别 SARS-CoV-2 的结构基础。
Science. 2020 Mar 27;367(6485):1444-1448. doi: 10.1126/science.abb2762. Epub 2020 Mar 4.
4
Clinical Characteristics of Coronavirus Disease 2019 in China.《中国 2019 年冠状病毒病临床特征》
N Engl J Med. 2020 Apr 30;382(18):1708-1720. doi: 10.1056/NEJMoa2002032. Epub 2020 Feb 28.
5
Type 2 angiotensin II receptor is downregulated in cardiomyocytes of patients with heart failure.2型血管紧张素II受体在心力衰竭患者的心肌细胞中表达下调。
Cardiovasc Res. 2000 Apr;46(1):73-81. doi: 10.1016/s0008-6363(00)00008-0.
Zotero 插件